Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia

Anusara Daenthanasanmak, Yuquan Lin, Meili Zhang, Bonita R. Bryant, Michael N. Petrus, Richard N. Bamford, Craig J. Thomas, Milos D. Miljkovic, Kevin C. Conlon, Thomas A. Waldmann

A R T I C L E   I N F O

Keywords:
Adult T cell leukemia
JAK1 inhibitors
mTOR inhibitors
Combination therapy
Smoldering/chronic ATL

A B S T R A C T

Adult T-cell leukemia (ATL) is an aggressive T-cell lymphoproliferative malignancy of regulatory T lymphocytes (Tregs), caused by human T-lymphotropic virus type 1 (HTLV-1). Interleukin 2 receptor alpha (IL-2Ra) is expressed in the leukemic cells of smoldering/chronic ATL patients, leading to constitutive activation of the JAK/STAT pathway and spontaneous proliferation. The PI3K/AKT/mTOR pathway also plays a critical role in ATL cell survival and proliferation. We previously performed a high-throughput screen that demonstrated additive/synergistic activity of Ruxolitinib, a JAK1/2 inhibitor, with AZD8055, an mTORC1/C2 inhibitor. However, effects of unintended JAK2 inhibition with Ruxolitinib limits its therapeutic potential for ATL patients, which lead us to evaluate a JAK1-specific inhibitor. Here, we demonstrated that Upadacitinib, a JAK-1 inhibitor, inhibited the proliferation of cytokine-dependent ATL cell lines and the expression of p-STAT5. Combinations of Upadacitinib with either AZD8055 or Sapanisertib, mTORC1/C2 inhibitors, showed anti-proliferative effects against cytokine-dependent ATL cell lines and synergistic effect with reducing tumor growth in NSG mice bearing IL-2 transgenic tumors. Importantly, the combination of these two agents inhibited in vivo spontaneous proliferation of ATL cells from patients with smoldering/chronic ATL. Combined targeting of JAK/STAT and PI3K/AKT/mTOR pathways represents a promising therapeutic intervention for patients with smoldering/chronic ATL.

Introduction

Adult T-cell leukemia (ATL) is a malignancy of regulatory T cells (Tregs), associated with human T-lymphotropic virus type 1 (HTLV-1) infection that is curable only with an allogeneic stem cell transplantation [1]. ATL is classified into four clinical subtypes: acute, lymphoma, smoldering, and chronic subtypes [2]. Although various molecular pathophysiological characteristics of ATL have been explored, the efficacy of current treatments is still limited, particularly in relapsed and refractory disease [3]. The HTLV-1-encoded transactivating protein Tax, interacts with numerous cellular factors that promote survival and immortalization of HTLV-1-infected T-cells [4]. Our group demonstrated that Tax transactivates two autocrine pathways of IL-2/IL-2Ra, IL-15/IL-15Ra and one paracrine pathway of IL-9 [5–7]. This activation led to the phosphorylation of JAK1, JAK3, and STAT5 with the subsequent entry of phosphorylated STAT5 into the nucleus. Abnormal activation of the JAK/STAT pathway is also prevalent in other types of T-cell malignancies [8]. Independently, JAK activation or STAT mutations are not adequate to initiate leukemic cell proliferation, but rather required the complete cascade of JAK activation and STAT phosphorylation. Therapeutic strategies targeting this pathway using small molecules have been conducted in numerous clinical trials [9,10].

Our group has previously demonstrated the additivity/synergy of drug combination between the JAK1/2 inhibitor, Ruxolitinib (Jakafi, ICN8018424), and BCL-XL inhibitor, Navitoclax in ATL models [11]. This combination was shown to inhibit the proliferation and tumor growth in a cytokine dependent ATL model and led to initiation of a Phase I/II clinical trial of Ruxolitinib for the treatment of ATL (NCT01712659). Although Ruxolitinib was previously approved by the FDA for the treatment of patients with myelofibrosis [9], long term ad-

Abbreviations: ATL, Adult T-cell leukemia; Tregs, Regulatory T lymphocytes; HTLV-1, Human T-lymphotropic virus type 1; JAK, Janus kinase; mTOR, Mammalian target of rapamycin.

* Corresponding author.

E-mail address: twald@mail.nih.gov (T.A. Waldmann).

These authors contributed equally to this work

https://doi.org/10.1016/j.tranon.2020.100913

Received 17 July 2020; Received in revised form 23 September 2020; Accepted 12 October 2020

1936-5233/Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ministration resulted in anemia and thrombocytopenia, likely due to its JAK2-inhibitory effects [12]. Thus, in this study, we focused on examining a specific JAK1 inhibitor to circumvent the off-target effect.

Upadacitinib, also known as ABT-494, is a potent and selective JAK1 inhibitor with a specificity of 60-fold and >100 fold over JAK2 and JAK3 respectively [13]. Upadacitinib was demonstrated to suppress paw swelling and bone destruction in a rat adjuvant-induced arthritis model indicating its efficacy in vivo. Moreover, Upadacitinib received FDA approval for the treatment of moderate to severe rheumatoid arthritis after demonstrating significant radiographic and symptomatic improvement in these patients [14]. However, we expected that monotherapy with a JAK inhibitor would be insufficient therapy for smoldering/chronic ATL patients. Thus, we have identified AZD8055, a mammalian target of rapamycin (mTOR) inhibitor from our high-throughput screening analysis as having profound additivity/synergy with Ruxolitinib. [11]. The therapeutic efficacy of Upadacitinib combined with mTOR inhibitors remain to be explored, particularly in smoldering and chronic ATL patients.

AZD8055 is a first-in-class agent of a second generation of mTOR inhibitor that was designed to target both mTORC1 and mTORC2 and act as an ATP-competitive inhibitor. mTOR is a conserved serine/threonine kinase that regulates many major cellular processes such as survival, proliferation and metabolism [15]. Constitutive activation of the mTOR pathway has been found in multiple types of cancer and two of the first generation mTOR inhibitors have been approved by FDA, temsirolimus for the treatment of advanced-stage renal cell carcinoma [16] and Everolimus for tuberous sclerosis [17]. These two agents are rapamycin analogs and only inhibit mTORC1, whereas mTORC2 is known to directly activate AKT on Ser473 that regulates cell survival, apoptosis [18]. Thus, treatment with these rapamycin analogs have limited clinical efficacy and are associated with drug resistance [19,20].

In contrast to the rapamycin analogs, AZD8055 inhibits the phospho-rylation of both mTORC1 and mTORC2 substrates; p70S6K and 4E-BP1 and p-AKT, respectively [21]. The safety profile, including pharmacokinetics and pharmacodynamics of AZD8055, has been evaluated in advanced solid tumors and lymphomas and demonstrated acceptable toxicity [22]. Another dual ATP-competitive mTORC1/C2 inhibitor, Sapanisertib, also exhibited therapeutic effects in phase I trials in multiple myeloma, non-Hodgkin’s lymphoma, and Waldenström’s macroglobulinemia patients [23].

In the current study, we demonstrated that Upadacitinib suppressed cell survival and proliferation of cytokine-dependent ATL cell lines and dual inhibition of mTORC1/C2 with AZD8055 or Sapanisertib was more effective than Everolimus’s mTORC1 inhibition alone. The combination of Upadacitinib with either AZD8055 or Sapanisertib showed synergistic effects on cytokine-dependent ATL cell lines, ATL cells from smoldering/chronic ATL patients, and in two xenograft models with NSG mice bearing tumors. These results indicate that the combination of JAK1i and mTORC1/2i has a significant promise as multi-agent therapy for patients with smoldering/chronic ATL.

Materials and methods

Reagents and cell lines

Upadacitinib (ABT494), AZD8055 and Sapanisertib were purchased from Medchem Express (Monmouth Junction, NJ). Human IL-2-dependent ATL cell lines; ED40515(+), ED41214(+), ATL55T(+) were kindly provided by Dr. Michiyuki Maeda (Kyoto University), KOB, LM-1, K1K1 were provided by Dr. Yasuaki Yamada (Nagasaki University). Cells were maintained in RPMI 1640 medium plus 10% FBS with 100U/mL recombinant human IL-2. Human IL-2-dependent ATL cell lines; ED40515(+), ED41214(+), and ATL43(+) were obtained from (Dr. Michiyuki Maeda, Kyoto University), ST1 (Dr. Tomoko Hata, Nagasaki University), Su9T01 (Dr. Naomichi Arima, Kagoshima University), ATN1 (Dr. Tomoki Naoe, Nagoya University) and MT1 (Dr. Miyoishi, Okayama University) and ALK(−) Anaplastic large cell lymphoma (ALCL) cell lines; FEPD, Mac-1, Mac2A, Mac2B, TLBR1, TLBR2 were maintained in RPMI complete medium without cytokine. Human foreskin fibroblast cells were purchased from ATCC (Gaithersburg, MD).

Cell proliferation assay

Twenty thousand ATL cells were seeded in 96-well plates and cultured for 72 h either in RPMI 1640 medium plus 10% FBS with 100U/mL recombinant human IL-2 alone or in serial dilutions of drug combinations. On day 3, the cells were pulsed with 1 μCi (0.037 MBq) of 3H-thymidine during the last 6 h of culture. The cells were then harvested with a Tomtec cell harvester (Hamden, CT) and counted with a MicroBeta2 microplate counter (PerkinElmer, Shelton, CT). The assay was performed in three independent experiments.

Intracellular staining of p-STAT5

Human IL-2-dependent ATL cell lines were cultured with 1 μM of Upadacitinib for 1, 4 and 24 h. Control groups were incubated with DMSO. The cells were harvested at different time points and fixed with BD Phosflow™ Lyse/Fix Buffer at 37°C for 10 min. After washing, the cells were permeabilized with cold BD Phosflow™ Perm Buffer III on ice for 30 min followed by staining with Anti-Stat5 (pY694), Clone 47/Stat5 (pY694) for 1 h in staining buffer at room temperature. Cells were collected on FACS Calibur analysis (BD Biosciences, San Jose, CA, USA), and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).

Annexin V staining

Cell apoptosis assay was performed according to the manufacturer’s instruction using an Annexin V apoptosis detection kit (BD Biosciences, San Jose, CA) and detected by flow cytometry. Cells were cultured with 1 μM of Upadacitinib or DMSO for 48 h and then labeled with Annexin V followed by FACS Calibur analysis. For patient’s peripheral blood mononuclear cells (PBMCs), after 6-day ex vivo culture without cytokine, the enriched tumor cells were further cultured with either DMSO, Upadacitinib, AZD8055 or in combinations for an additional 48 h and cells were subjected for Annexin V staining.

Cell cycle analysis

ATL cell lines were cultured with 1 μM of AZD8055 or Everolimus or DMSO for 24 h. The cells were then labeled with 10 μM BrdU for 45 min. The BrdU-pulsed cells were stained according to the BrdU Flow Kit staining protocol (BD Biosciences, San Jose, CA, USA) and analyzed using a FACS Calibur flow cytometry.

Mouse model of ED40515(+)/IL-2 and therapeutic study

The ED40515(+)/IL-2 cell line was generated as previously described [11]. The xenograft tumor model of human IL-2-dependent ATL was established by subcutaneous injection of 1×10⁷ ED40515 (+)/IL-2 cells into the right flank of female NOD.Cg-Pkdckm/IL2rgtm1Jp/J/SzJ (NSG) mice (The Jackson Laboratory, Bar Harbor, ME). Treatment was started ten days after tumor inoculation when the average tumor volume reached approximately 100 mm³. Upadacitinib was dissolved in 30% PEG300 (Sigma-Aldrich, St. Louis, MO) at a dose of 6 mg/kg per day by osmotic pump insertion or via the oral route daily for two weeks. AZD8055 (15 mg/kg/day) or Sapanisertib (1 mg/kg/day) were dissolved in 30% PEG300 and given orally for five times/week. Combination treatment was administered at the same dose and dosing schedules. Control mice receiving 30% PEG300 dissolved in water were used as a vehicle group. Tumor growth was monitored by measuring tumor size in two orthogonal dimensions with tumor volume calculated using the formula 0.5 (long dimension) x (short dimension)². The level of
human sIL-2Ra in serum of treated mice was measured using enzyme-linked immunosorbent assays (ELISA) (R&D Systems, Minneapolis, MN). All animal experiments were approved by the National Cancer Institute Animal Care and Use Committee (NCI ACUC) and were performed in accordance with NCI ACUC guidelines.

**Ex vivo cultures of PBMCs from ATL patients**

Peripheral blood samples were obtained from patient volunteers with chronic and smoldering ATLs under the care of the Clinical Trials Team, Lymphoid Malignancies Branch, NCI. This study protocol was approved by the Institutional Review Board of the NCI. Informed consent was obtained in writing from patients. The proliferation assay of ex vivo 6-day culture was performed as described previously [11]. Prior to ex vivo culture, we screened for the smoldering/chronic ATL patients by measuring CD4^+^CD25^+^ in patient’s blood using flow cytometry. PBMCs were isolated from patient blood by ficoll density gradient centrifugation and then cultured ex vivo in RPMI 1640 medium containing 10% FBS without cytokines either with DMSO or increasing doses of Upadacitinib, AZD8055 or in combination for 6 days. No stimuli were added to the culture to let the IL-2Ra^+^ leukemic cells activate, expand and enrich. The leukemic cells were pulsed during the last 6 h of incubation with 1 μCi of ^3^H-Thymidine, and then harvested and counted with a MicroBeta 2 microplate counter.

**Western blot analysis**

Whole-cell lysates were collected using lysis buffer supplemented with the protease inhibitor cocktail according to the manufacturer’s protocol, MCL-1 from Sigma-Aldrich (St. Louis, MO). Cell lysates were electrophoresed on 4-12% Bis-Tris Novex gel and blotted onto polyvinylidene difluoride membranes from Invitrogen (Carlsbad, CA). Proteins were detected by immunoblotting after blocking. Antibodies were from Cell Signaling Technology Inc. (Danvers, MA); p-STAT5 (#9359), STAT5 (#94205), p-STAT3 (#9145), p-akt-Ser473 (#4060), AKT (#9272), p-4E-BP1 (#2855), GAPDH (#5174). Monoclonal anti-β-actin antibody (AC-74) was purchased from Sigma-Aldrich. Signal intensity was quantified with ImageJ software.

**Statistical analysis**

For comparison between control, single agent and combination groups, one-way ANOVA was used to determine statistical significances. The two-way ANOVA was performed in the cell cycle analysis assay (GraphPad Prism software, version 7). For patient data, Mann-Whitney test was performed to determine statistical differences between groups. p-value <0.05 was considered statistically significant.

**Results**

**JAK1 inhibition with Upadacitinib inhibited proliferation and phosphorylation of STAT5 in cytokine-dependent but not cytokine-independent ATL cell lines**

We previously demonstrated that the JAK1/2 inhibitor, Ruxolitinib diminished cell growth and proliferation of cytokine-dependent ATL but has limited potential as a therapeutic strategy [11]. To address the dose-limiting effects of JAK2 inhibition with Ruxolitinib, we evaluated a JAK1 inhibitor (Jak1i) with its better pharmacodynamics and specificity as an alternative to Ruxolitinib. Upadacitinib was highly effective as an inhibitor that inhibited the survival and proliferation of IL-2-dependent ATL cell lines; ED40515 (+), ED41214 (+), ATL55T (+), KK1, KOB and LMY1. Limited or no inhibition was observed in the seven cytokine-independent ATL cell lines; ED40515 (-), ED41214 (-), ATL437T (-), ATN1, MTI, ST1 and Su9T01, which further demonstrating its specificity for JAK1 (Fig. 1A). Furthermore, p-STAT5 expression was reduced at 24 h in the IL-2-dependent cell lines after JAK1 blockade (Fig. 1B). These results are consistent with our previous study [11] demonstrated that six IL-2-independent ATL cell lines did not express p-STAT5, therefore, JAK1i had no effect on the cytokine-independent ATL cell proliferation.

Ruxolitinib has a short half-life of approximately 3 h, which requires at least twice daily (b.i.d.) administration [24] whereas with Upadacitinib’s half-life of 6-16 h would probably allow for less frequent dosing [10]. Thus, we sought to determine the pharmacodynamics of Upadacitinib in inhibiting p-STAT5 in IL-2-dependent cell lines. Upadacitinib exhibited longer pharmacodynamic effects with a robust inhibition of p-STAT5 at 1 h that was maintained for up to 4 h. The p-STAT5 expression increased at 24 h but had not reached the baseline (Fig. 1C).

Furthermore, we evaluated the effect of Upadacitinib on cell apoptosis with Annexin V staining. Upadacitinib induced apoptosis in cytokine-dependent ATL cell lines, ED40515(+) and LMY1 cell lines after 48 h of treatment, whereas fibroblasts did not respond to the inhibitor (Fig. 1D).

**Dual inhibition of mTORC1/C2 with AZD8055 was more effective than the single mTORC1 inhibitor Everolimus, in cytokine-dependent ATL cell lines**

From our high-throughput screening results, AZD8055, an mTORC1/C2 inhibitor, demonstrated an additive/synergistic effect with Ruxolitinib suggesting that the PI3K/AKT/mTOR pathway was essential for ATL cell survival. We confirmed the screening results by performing a cell proliferation assay with AZD8055. In parallel, we also evaluated another FDA-approved mTORC1 inhibitor, Everolimus. As seen in the dose response curves, AZD8055 had an antiproliferative effect against 13 ATL cell lines regardless of cytokine-dependency. In contrast, Everolimus had little effect on ATL cell line proliferation (Fig. 2A). The IC50 of IL-2-dependent and IL-2-independent cell lines treated with AZD8055 or Everolimus were determined and summarized on Supplementary Table S1. Similar results were previously described in ATL cell lines with ED40515 (+), Hut102 (-), MT2 (-) and ATL437 (+) by Kawata and colleagues [25] who showed that dual inhibition of mTORC1 and mTORC2 was more effective than single blockade of mTORC1 as mTORC2 has the ability to directly activate AKT that in turn augments cell survival. We also examined phosphorylated AKT at Ser-473, a direct substrate of mTORC2, in the six IL-2 dependent ATL cell lines and found that only AZD8055 but not Everolimus inhibited AKT phosphorylation (Fig. 2B) suggesting that dual targeting of mTORC1/C2 is required to suppress ATL cell proliferation. We further examined the effects of AZD8055 and Everolimus on the cell cycle analysis. We demonstrated that AZD8055 markedly induced cell-cycle arrest at the G0/G1 phase in ED40515(+) (p<0.0001), ATL55T (+) (p<0.0001) and KK1 (p<0.0395) cell lines compared to the Everolimus-treated or DMSO groups (p>0.0001). Moreover, the cells entering S phase were significantly decreased in the AZD8055-treated group compared to the DMSO control (p<0.0001) group or the Everolimus-treated group in ED40515(+) (p<0.0001), ATL55T(+) (p<0.0001), and KK1 (p=0.0418) cell lines (Fig. 2C).

**The combination of Upadacitinib and AZD8055 showed synergistic effect with cytokine-dependent ATL cell lines**

As a result of additive/synergistic effects between Ruxolitinib and AZD8055, we hypothesized that Upadacitinib with AZD8055 would display the same effect. We initially examined these combinations in primary T cells stimulated with anti-CD3 and anti-CD28 in which the activation of JAK/STAT and PI3K/Akt/mTOR pathways are known to be pervasive. The combinations of these two inhibitors, Upadacitinib (15.6 nM to 250 nM) and AZD8055 (31.2 nM to 500 nM) were synergistic in inhibiting T-cell proliferation with increasing doses of this drug combination evaluated in four different PBMCs populations isolated from healthy donors (Supplementary Fig. 1). Consistently, Upadacitinib and AZD8055 showed synergistic effect with the six cytokine-dependent
ATL cell lines (Fig. 3) while the same treatment had no effect on fibroblast proliferation, demonstrating the specificity of these effects on ATL cell lines. Because cytokine–independent ATL cell lines did not respond to the JAK1 inhibitor, the synergistic effect of these two inhibitors was not observed in these cell lines (Supplementary Fig. 3). To measure synergistic effect between Upadacitinib and AZD8055, we used Chou-Talalay method [26] to quantify whether the interaction is additive or synergistic. The combination index (CI) values were generated when two drugs were combined at a constant ratio. CI values less than 1 indicates synergism. The synergistic effect of this drug combination was observed in six IL-2 dependent ATL cell lines with CI values less than 1 over five different concentrations (Supplementary Table 2). CI plots of synergism represents each individual combination data point in Supplementary Fig. 2.

**Therapeutic effects of the Upadacitinib and AZD8055 combination in suppressing tumor growth in xenograft mice bearing ED40515(+) IL-2 transgenic tumors and ALK (-) ALCL tumors**

To evaluate the efficacy of this combination in vivo, we used the ED40515(+) cell line that expresses the human IL-2 transgene with a retroviral system [11]. The ED40515(+) IL-2 transgenic tumor has the ability to grow in immunodeficient NOD/SCID/γ−/− (NSG) mice without an external supply of human IL-2 cytokine. Upadacitinib was administered either by continuous infusion pump (Fig. 4A) or orally (Supplementary Fig. 4A). The results of treatment showed that Upadacitinib suppressed the tumor growth via infusion pump better than by the oral route. Single agents of Upadacitinib or AZD8055 delayed the tumor growth in tumor-bearing mice compared to vehicle control mice. The combination therapy with Upadacitinib and AZD8055 dramatically reduced tumor volumes compared with single agents alone, whereas Upadacitinib combined with Everolimus showed little effect (Supplementary Fig. 4B). Furthermore, we determined the level of soluble IL-2Rα, which is a surrogate tumor marker, in the serum of treated mice after two weeks of treatment. Consistent with the decreased tumor volume, the level of sIL-2Rα was meaningfully reduced in the combined-treatment group with Upadacitinib and AZD8055 compared to single agent-treated mice (Fig. 4B).

We further examined another xenograft mouse model that involves an ALK (-) ALCL tumor wherein the JAK/STAT pathway was also reported to be activated in ALK(−) ALCL patients [27]. Similar results were also observed when the TLBR1 cell line was implanted. Treatment with
Upadacitinib or AZD8055 alone moderately diminished tumor growth. Notably, the combination of Upadacitinib and AZD8055 significantly suppressed tumor growth as evidenced by decreased cell proliferation and tumor volume in the combined-treated group (Fig. 4C-D). These in vivo results correlated with the decreased cell proliferation, p-STAT3 and p-AKT expressions in ALC1 cell lines (Supplementary Fig. 5A-B).

Antiproliferative effect of the Upadacitinib and AZD8055 combination on the 6-day ex vivo spontaneous proliferation of ATL cells isolated from patients with smoldering/chronic ATL

Our established 6-day ex vivo culture of PBMCs containing ATLs from patients with smoldering/chronic ATL demonstrated the activation of JAK/STAT signaling associated with spontaneous leukemic cell proliferation. We previously demonstrated that the leukemic cells of smoldering/chronic ATL patients constitutively expressed IL-2Ra whereas resting normal T cells do not express this marker [28]. This autonomous proliferation of leukemic cells in smoldering/chronic ATL patients occurs in an IL-2/IL-2Ra dependent manner but it also requires autologous monocytes to fully induce proliferation via cell-cell contact [7]. In contrast, PBMCs from acute ATL patients do not proliferate or proliferated independent of cytokines. Therefore, autocrine stimulation by IL-2/IL-2Ra interaction is not observed in acute ATL patients.

Prior to ex vivo culture, we screened for smoldering/chronic ATL patients by measuring CD4+CD25+ in patient’s blood by flow cytometry. No stimuli were added throughout 6-day culture to let the IL-2Ra+ leukemic cells activate, expand and enrich. Robust inhibition of ATL cells in ex vivo culture proliferation was demonstrated in five ATL patients when Upadacitinib and AZD8055 were added to the cultures. Cell proliferation was inhibited more than 95% when the combination of 250 nM Upadacitinib and 500 nM AZD8055 were used (Fig. 5A). The CI values indicates synergistic effect of this drug combination are shown on Supplementary Table 3. We further examined the molecular pathways present on the leukemic cells when the number of ATL cells were enriched after 6 days. By culturing the ex vivo cultured ATL cells with the drug combination, Upadacitinib potently inhibited p-STAT5 and AZD8055 suppressed the expression of p-AKT and p-4EBP1 which is in line with the results of the cell proliferation assay (Fig. 5B). Induction of cell apoptosis was also enhanced in the combination-treated group (Fig. 5C).
The combination of Upadacitinib and AZD8055 showed synergy with cytokine–dependent ATL cell lines. The combined effects of Upadacitinib with AZD8055 inhibitors on six IL-2–dependent ATL cell lines incubated for 72 h in the presence of five increasing concentrations of Upadacitinib (blue), AZD8055 (orange), or their combinations (green). Fibroblast cells were used as a control. A thymidine incorporation assay was performed, and percentages of control were calculated from the counts per minutes (cpm) of samples with drugs divided by the cpm of samples with no inhibitor x 100. Representative figures of three independent experiments are shown.

Therapeutic effects of the Upadacitinib and AZD8055 combination in suppressing tumor growth in xenograft mice bearing ED40515(+)/IL-2 transgenic tumors and ALK (-) ALC tumor.

Ten million ED40515(+)/IL-2 or 5 x 10⁶ TLBR1 cell lines were subcutaneously implanted in NSG mice. The therapy was started when average tumor volumes reached around 100 mm³. Upadacitinib was administered by pump at a dose of 6 mg/kg/day and AZD8055 was given orally at a dose of 15 mg/kg for 14 days. The vehicle group received 30% PEG300 dissolved in water. (A) Average tumor volumes during the therapeutic time course were measured twice weekly until the tumor volume reached 2000 mm³ (n=10-12). (B) Serum levels of human soluble IL-2Rα (sIL-2Rα) were measured on day 14 after treatment with ELISA assay. Two independent experiments were performed, and data were pooled together. (C) The combined effects of Upadacitinib with AZD8055 inhibitors on the TLBR1 cell line incubated for 72 h in the presence of five different drug concentrations and cell proliferation was measured with a thymidine incorporation assay. Representative figures of three independent experiments are shown. (D) Average tumor volumes were measured during the therapeutic time course of drug combination on the TLBR1 model (n=5-6). One-way ANOVA was performed to determine statistical differences **p < 0.01, ***p < 0.0001.
The combination of Upadacitinib and Sapanisertib showed synergistic effect with cytokine-dependent ATL cell lines, PBMCs containing ATL cells from ATL patients and in a xenograft mouse model.

AZD8055 displayed anti-proliferative effects against ATL cell lines, however, the clinical development of this inhibitor has not been advanced meaningfully due to treatment related abnormal liver functions [22]. Therefore, we examined another mTORC1/C2 inhibitor with similar efficacy as AZD8055. Sapanisertib is an oral ATP-dependent mTORC1/C2 inhibitor that showed potent antitumor activity by suppressing in a metastatic prostate cancer model [29]. Moreover, Sapanisertib is currently being evaluated in clinical trials for various types of cancer [23,30]. In examining the dose response curves of Sapanisertib in IL-2 dependent ATL cell lines, Sapanisertib demonstrated anti-proliferative effects similar to those by AZD8055 (Fig. 6A). However, the AZD8055 showed higher potency in cytokine-independent ATL cell lines as IC50 of AZD8055 is slightly lower than Sapanisertib (Supplementary Table S1). Fibroblasts were used as a negative control to confirm drug specificity. The level of cell inhibition also correlated with the decreased expression of p-AKT at Ser-473 (Fig. 6B). Furthermore, the combination of Upadacitinib with Sapanisertib demonstrated synergistic effect in six cytokine–dependent ATL cell lines (Supplementary Fig. 6 and Supplementary Table 4) and in ATL cells from PBMCs isolated from two patients with smoldering/chronic ATL (Fig. 6C and Supplementary Table 5). Importantly, similar therapeutic efficacy in vivo of this drug combination was also observed in xenograft mice bearing ED40515(+)/IL-2 transgenic tumors (Fig. 6D) comparable to that observed in the combination with AZD8055.

Discussion

Previously, we demonstrated that the JAK/STAT pathway is critical for smoldering/chronic ATL cell survival and JAK1/2 inhibition with Ruxolitinib blocked STAT5 phosphorylation and reduced proliferation of IL-2–dependent ATL cell lines [11]. However, JAK2 is involved in the regulation of the platelet and red blood cell production as thrombopoietin and erythropoietin receptors utilize JAK2 for signaling, thus, the effects of JAK2 inhibition by Ruxolitinib led to adverse events of anemia and thrombocytopenia [12]. In the present study, we sought to replace Ruxolitinib with a specific JAK1 inhibitor to address this concern while enhancing specificity. Our current work demonstrates that Upadacitinib is highly specific for JAK1 and its efficacy could be enhanced...
by combining with mTORC1/C2 inhibitors in smoldering/chronic ATL model.

The Tax protein of HTLV-1 transactivates IL-2Ra on smoldering/chronic ATL cells leads to the activation of JAK/STAT pathway and spontaneous cell proliferation. However, with acute ATL or some transformed cells, they do not rely on JAK/STAT for survival and growth. Thus, this combination therapy targeting JAK1 and mTOR pathways could only be applied with smoldering/chronic ATL and not on acute ATL patients [28]. It has been suggested that ATL cells progressing away from cytokine dependence continue to accumulate transforming mutations and epigenetic changes [31] [32]. Deciphering the potential differences between cytokine dependent and independent ATL cells could prove valuable at the level of therapeutics.

The utilization of JAK1 inhibitor may have broader application against other types of T cell malignancies possessing an activated JAK/STAT pathway such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [33] or ALK (-) ALCI patients [34] as the autocrine IL-2/IL-2Ra loop mediates spontaneous proliferation, is also present in these patients. For ALK (-) ALCI patients, the 5-year overall survival rate was poorer than ALK (+) with 49% and 70% respectively [35]. ALK (-) ALCI patients were generally responsive to standard first-line treatment of chemotherapy regimens but tumor relapse often occurred [36,37]. Our results indicate that the combination of JAK1i and mTORC1/C2i inhibition treatment has significant potential in a disease driven by JAK/STAT activation including ALK (-) ALCI cells (Fig. 4C-D), which rely on IL-6 signaling through JAK1/JAK2/STAT3 pathway [34].

Preclinical evaluation of several FDA-approved mTOR inhibitors, rapamycin analogs, demonstrated limited efficacy suggesting that mTORC1 targeting alone is insufficient [19,20]. Kawata and colleagues [25] demonstrated superior efficacy of the dual inhibitors, PP242 and AZD8055, compared to mTORC1 inhibitors, rapamycin and Everolimus with ATL cell lines which have the benefit of blocking the AKT feed-back activation loop. In our study with cytokine-dependent cell lines, we noted similar effects with AZD8055 that also inhibited p-AKT (S-473) and was more efficient in inducing cell cycle arrest and in suppressing the tumor growth than Everolimus. These results suggest that dual inhibition of mTOR is required for effective treatment of ATL patients.

Nevertheless, patients treated in a phase I clinical trial of AZD8055 showed hepatic dysfunction with elevated levels of transaminases that precluded further clinical development [22]. Such liver function abnormalities were not observed with other mTORC1 inhibitors such as Temsirolimus and Everolimus. Therefore, we investigated another dual mTOR inhibitor, Sapanisertib. In the first clinical trial of Sapanisertib in hematologic malignancies, it was well tolerated, and patients exhibited partial responses in relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström macroglobulinemia. This study also suggested that Sapanisertib could be used in combination with other agents as it showed limited efficacy as a single agent [23].

Taken as a whole, our preclinical studies suggest the importance of the JAK/STAT and PI3K/AKT/mTOR signaling pathways in the survival of smoldering or chronic ATL malignant lymphocytes. The combination of Upadacitinib with Sapanisertib demonstrated high potency and synergy and supports a proposed Phase I/II clinical trial with this two-agent combination for smoldering/chronic ATL patients.

Declaration of Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank the NIH Fellows Editorial Board for critical reading and editing the manuscript. This project was supported by the Intramural Research Program of the National Cancer Institute, NIH and in part by the Division of Preclinical Innovation, National Center for Advancing Translational Sciences. This study was performed under the conditions of the World Medical Association’s Declaration of Helsinki. All patients signed a written informed consent for participation in clinical studies. Clinical studies were approved by the Intramural Review Board of the National Cancer Institute. Animal studies were approved by the NCI Animal Care and Use Committee.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2020.100913.

References

[1] L.B. Cook, et al., Revised adult T-Cell leukemia/lymphoma international consensus meeting report, J. Clin. Oncol. 37 (8) (2019) 677–687.
[2] M. Shimoyama, Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87), Br. J. Haematol. 79 (3) (1991) 428–437.
[3] L. Malpica, et al., Epidemiology, clinical features, and outcome of HTLV-1-related ATL in an area of prevalence in the United States, Blood Adv. 2 (6) (2018) 607–620.
[4] M. Matsuoka, K.T. Jeang, Human T-cell leukemia virus type 1 (HTLV-1) infectivity and cellular transformation, Nat. Rev. Cancer 7 (4) (2007) 270–280.
[5] C.L. Tendler, et al., Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotrophic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy, Proc. Natl. Acad. Sci. U S A 87 (12) (1990) 5218–5222.
[6] N. Azimi, et al., Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site, Proc. Natl. Acad. Sci. U S A 95 (5) (1998) 2452–2457.
[7] J. Chen, et al., Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia, Blood 116 (26) (2010) 5948–5956.
[8] T.A. Waldmann, J. Chen, Disorders of the JAK/STAT Pathway in T cell lymphoma pathogenesis: implications for immunotherapy, Annu. Rev. Immunol. 35 (2017) 533–550.
[9] S. Verstovsek, et al., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N. Engl. J. Med. 363 (12) (2010) 1117–1127.
[10] M.F. Mohamed, et al., Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis, Clin. Pharmacokinet. 55 (12) (2016) 1547–1558.

[11] M. Zhang, et al., Selective targeting of JAK-STAT signaling is potentiated by Bcl-2 blockade in IL-2-dependent adult T-cell leukemia, Proc. Natl. Acad. Sci. U S A 112 (40) (2015) 12480–12485.

[12] S. Verstovsek, et al., A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N. Engl. J. Med. 366 (9) (2012) 799–807.

[13] J.M. Parmentier, et al., In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494), BMC Rheumatol. 2 (2018) 23.

[14] M.C. Genovese, et al., Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial, Lancet 391 (10139) (2018) 2513–2524.

[15] R.A. Saxton, D.M. Sabatini, mTOR signaling in growth, metabolism, and disease, Cell 168 (6) (2017) 966–976.

[16] G. Hudes, et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N. Engl. J. Med. 356 (22) (2007) 2271–2281.

[17] J.A. French, et al., Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study, Lancet 388 (10056) (2016) 2153–2163.

[18] O.D. Sarbasov, et al., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science 307 (5712) (2005) 1098–1101.

[19] C.E. Chamberlain, et al., A patient-derived xenograft model of pancreatic neuroendocrine tumors identifies sapanisertib as a possible new treatment for everolimus-resistant tumors, Mol. Cancer Ther. 17 (12) (2018) 2702–2709.

[20] C. Caro-Vegas, et al., Targeting mTOR with MLN0128 overcomes rapamycin and chemoresistant primary effusion lymphoma, mBio 10 (1) (2019).

[21] C.M. Chresta, et al., AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity, Cancer Res. 70 (1) (2010) 288–298.

[22] A. Naing, et al., Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma, Br. J. Cancer 107 (7) (2012) 1093–1099.

[23] L.M. Ghobrial, et al., TAK-228 (formerly MLN0128), an investigational oral dual mTORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom’s macroglobulinemia, Am. J. Hematol. 91 (4) (2016) 400–405.

[24] J.G. Shi, et al., The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers, J. Clin. Pharmacol. 51 (12) (2011) 1644–1654.

[25] T. Kawata, et al., Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia, Cancer Sci. 109 (1) (2018) 103–111.

[26] T.C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 70 (2) (2010) 440–446.

[27] R. Crescenzo, et al., Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma, Cancer Cell 27 (4) (2015) S16–S32.

[28] T.A. Waldmann, et al., The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphoproliferative virus I-induced adult T-cell leukemia, Blood 82 (6) (1993) 1701–1712.

[29] A.C. Ihieh, et al., The translational landscape of mTOR signalling steers cancer initiation and metastasis, Nature 485 (7396) (2012) 55–61.

[30] H.A. Burris 3rd, et al., TAK-228 (formerly MLN0128), an investigational dual mTORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies, Cancer Chemother. Pharmacol. 80 (2) (2017) 261–273.

[31] Y. Kogure, K. Kataoka, Genetic alterations in adult T-cell leukemia/lymphoma, Cancer Sci. 108 (9) (2017) 1719–1725.

[32] M. Maeda, et al., IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-I-Infected T Cells to Develop Adult T-Cell Leukemia, Front. Microbiol. 11 (2020) 556.

[33] W. Ju, et al., CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP, Blood 117 (6) (2011) 1928–1946.

[34] J. Chen, et al., Cytokine receptor signaling is required for the survival of AKL-anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations, Proc. Natl. Acad. Sci. U S A 114 (15) (2017) 3975–3980.

[35] E.Y. Kao, D.T. Lynch, Cancer, AKL Negative Anaplastic Large Cell Lymphoma, St. Pearls, St. Pearls Publishing St. Pearls Publishing LLC., Treasure IslandFL, 2020.

[36] B. Pro, et al., Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, Blood 130 (25) (2017) 2709–2717.

[37] S. Horvitz, et al., Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (EChelon-2): a global, double-blind, randomized, phase 3 trial, Lancet 393 (10168) (2019) 229–240.